<DOC>
	<DOCNO>NCT01977443</DOCNO>
	<brief_summary>A randomized , double-masked , placebo-controlled , multi-centre phase IIa proof-of-concept study evaluate efficacy safety APD-209 Eye drop treatment acute phase adenovirus-induced EKC . The aim study investigate therapeutic efficacy APD-209 Eye drop measure adenoviral load , time viral eradication , clinical resolution EKC ( objective subjective assessment ) , presence opacity , visual acuity frequency second eye infection , assess safety tolerability APD-209 Eye drop EKC infected eye .</brief_summary>
	<brief_title>Therapeutic Efficacy APD-209 Eye Drops Treatment Epidemic Keratoconjunctivitis ( EKC )</brief_title>
	<detailed_description />
	<mesh_term>Conjunctivitis</mesh_term>
	<mesh_term>Keratoconjunctivitis</mesh_term>
	<mesh_term>Conjunctivitis , Viral</mesh_term>
	<mesh_term>Ophthalmic Solutions</mesh_term>
	<mesh_term>Tetrahydrozoline</mesh_term>
	<criteria>The patient meet follow criterion eligible enter study : Willing able provide inform consent . Men woman age 18 year onset adenoviral EKC symptom least one eye , clinically diagnose symptom appear within less 7 day time give informed consent . Using adequate contraceptive measure Known suspect allergy ingredient IMP placebo . Symptoms correlate EKC since 7 day . Diagnosis significant disease ( ) EKC eye . Diagnosis bacterial fungal ocular infection . Use antibiotic corticosteroid route ( except intravitreal corticosteroid ) within 14 day prior inclusion . Ocular antibiotic may , however , use 2 hour prior first dose IMP , thereafter prohibit study . Use immunosuppressive medication ( include intravitreal corticosteroid ) within 6 month prior inclusion . Use antiviral medication within 7 day prior inclusion . Usage medication herbal medicinal product document adverse reaction affect eye . Usage medication herbal medicinal product ocular administration inclusion . Female patient : currently pregnant breastfeed intend become pregnant study period . Known suspect drug abuse . Usage contact lenses study . Participation interventional clinical study within 30 day prior inclusion</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>